PFS Prolonged With Continuous Dabrafenib, Trametinib in Melanoma

WEDNESDAY, April 29, 2020 -- For patients with advanced BRAFV600E/K melanoma, continuous treatment with dabrafenib and trametinib improves progression-free survival (PFS) versus intermittent treatment, but overall survival is no different between...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news